### **Overview** Albert David Limited (ADL) is a well-established Indian pharmaceutical company headquartered in **Kolkata, India**, with a strong focus on innovation, quality manufacturing, and strategic expansion. The company operates in the **pharmaceutical sector**, manufacturing and marketing **allopathic and herbal formulations, intravenous (I.V.) infusions, medical disposables**, and specialized **placenta extract-based therapies**. ADL operates manufacturing facilities in **Kolkata, Ghaziabad, and previously in Mandideep**, and maintains a robust **distribution network** through sales depots in key cities including Kolkata, Lucknow, Patna, and others. --- ### **Product Launches & Portfolio Expansion (FY 2024–25)** ADL has made significant strides in product innovation during fiscal year 2024–25: #### **Gynecology Segment (7 New Launches)** - Alamin Woman - Nectagen - Alstat TA - Spasna M - Evacure Total - Proguard - Vaginova #### **Orthopedic Segment (4 New Launches)** - C3H OA Tabs - DhupCal Tabs - Sionueron NT Tabs - Alamin TKR sachets - In earlier periods, the company launched **Evaston OD 10 mg**, **Alamin SE**, **Evacure**, and **C3H**, indicating a consistent and growing product pipeline. - Ongoing commercialization of **Evaston**, a high-potential product, reflects the company's focus on innovative therapies. ADL is actively **building prescriber bases** and **engaging Key Opinion Leaders (KOLs)** to strengthen market acceptance and brand equity for these new launches. --- ### **Sales & Operational Strategy** - In **July 2025**, ADL **restructured its domestic field operations** into **five specialized sales forces**, each aligned with specific medical specialties. This enhances customer reach, improves targeting, and supports segment-specific growth. - The company has strengthened key departments to improve **operational resilience** and adapt to evolving market dynamics. - **Strategic Business Focus Areas**: - **Exports** - **Institutional Sales** - **Generics Business** --- ### **Research & Development (R&D) Excellence** ADL’s **Kolkata-based R&D center**, recognized by the **Department of Scientific and Industrial Research (DSIR)** since **2013**, is a cornerstone of its innovation strategy. #### **Core R&D Focus Areas:** - Formulation & API development - Process improvement and quality enhancement - Technical troubleshooting - Human placenta extract (HPE)-based products and their combinations #### **Key R&D Highlights:** - **Placentrex Research**: - Collaborating with **IIT Kharagpur** (Department of Biotechnology) on a research project investigating **Placentrex's mechanism** in **inhibiting bacterial growth** and **biofilm formation**, with **promising initial results**. - Standardizing bio-constituents in placenta-based formulations for inclusion in labeling, enhancing **scientific credibility and marketing claims**. - Ongoing studies to identify **growth factors, interleukins, and anti-inflammatory markers** for new therapeutic applications. - Development of new **Placentrex-based products** with **global patent potential**, targeting **immunomodulation** and **anti-biofilm activity**. - Research into **oral drug delivery systems and nutraceuticals** based on Placentrex. - **Patent Initiatives**: - Filed **provisional patent** for *“Therapeutic Components of Human Placental Extract and Process of Preparation Thereof”*. - Additional patents filed for **combination formulations** to improve clinical efficacy. - **External Collaborations**: - Partnerships with premier institutions: **CSIR, IITs, IICB, IISc, DST, DRDO**, and international research partners in the **US and EU**. - Focus on developing **advanced drug delivery systems** for domestic and export markets. - **Miltefosine Project**: - Developed a **WHO-compliant manufacturing process** for **Miltefosine**, a crucial drug for treating **leishmaniasis** (PKDL, ML, CL). - Established a **new API production facility in Kolkata** for technology transfer and scale-up. - **10 mg capsule batches** completed; **50 mg batches in progress** to meet international regulatory standards. --- ### **Manufacturing & Distribution Network** - **Manufacturing Plants**: - **Kolkata** (including new API facility for Miltefosine) - **Ghaziabad** - **Sales Depots**: - **Kolkata, Lucknow, Patna**, and previously **Delhi, Mumbai, Chennai, Bhopal, Guwahati, Vijaywada, etc.**, ensuring pan-India presence. --- ### **Exports & Global Expansion** - **Export Markets**: - Latin America - Southeast Asia - Select countries in North & East Africa - Targeting **CIS countries** for future expansion - **Export Strategies**: - Increasing **regulatory filings** to register more products in existing markets. - **Collaborating with established partners** to accelerate growth in Southeast Asia and CIS regions. - As of 2021, reported **foreign exchange earnings of ₹1,270.63 lakhs** with **spending of ₹1,156.44 lakhs**, indicating a **positive forex balance**.